reports hero background
Updated: Aug 17, 2026
ATHE Logo

Alterity Therapeutics

NASDAQ:ATHE·Stock Analysis Report
Day Range
$4.51 - $4.72
Market Cap
83.38M
P/E Ratio
0.0000
Avg Value
$4.28
Year Range
$2.66 - $5.89
$4.67$0.22 (4.94%)
1
General Information
Alterity Therapeutics Ltd is a clinical-stage biotechnology company focused on neurodegenerative diseases and the creation of a chemical library of proprietary molecules.

Its research and clinical development efforts are focused on Parkinson's disease and related disorders, where it is identifying and developing novel compounds that address the underlying pathology of these disorders by binding and redistributing excess labile iron, reducing alpha-synuclein aggregation, and rescuing neurons in the brain. Its pipeline programs are ATH434-201, ATH434-202, bioMUSE, ATH434, and Drug Discovery. The Group operated in one segment, research and development into Parkinsonian and other neurodegenerative disorders.

2
Alterity Therapeutics (ATHE) Stock Graph
3
How We Grade Alterity Therapeutics (ATHE)

We grade stocks based on past performance, their future growth potential, intrinsic value, dividend history, and overall financial health.

The chart below shows how we grade Alterity Therapeutics (ATHE) across the board compared to its closest peers.

4
Benzinga Edge Rankings

Benzinga Edge stock rankings give you four critical scores to help you identify the strongest and weakest stocks to buy and sell.

Momentum measures a stock's relative strength based on its price movement patterns and volatility over multiple timeframes, ranked as a percentile against other stocks.

Stock Score Locked: Want to See it?
Benzinga Rankings give you vital metrics on any stock – anytime.
5
Peer Ratings

See how Alterity Therapeutics compares to its peers in these key performance metrics from Benzinga Rankings.

Top Peers
Value
Quality
Growth
Momentum
Short
Medium
Long
ACRVAcrivon Therapeutics
N/A
N/A
N/A
N/A
CTORCitius Oncology
N/A
N/A
N/A
N/A
MAIAMAIA Biotechnology
N/A
N/A
N/A
N/A
ELTXElicio Therapeutics
N/A
N/A
N/A
0.55
Short: price trend over the last couple of months
Medium: price trend over the last couple of quarters
Long: price trend over the past year
Stock Score Locked: Want to See it?
Benzinga Rankings give you vital metrics on any stock – anytime.
6
Future Growth
Our estimate of future price growth is based on an aggregation of 0 analyst ratings over the past 3 months and their 12-month price targets.

Below, you can see that analysts are estimating a 12-month price target range of $10.00 - $16.00 with an average of $12.67

175.36%
Expected movement for Alterity Therapeutics (ATHE) over the next 12 months
Based on these rankings

Recent Ratings for Alterity Therapeutics (ATHE)

7
Past Performance
How has Alterity Therapeutics (ATHE) performed over the past 5 years?

The two main factors that we consider when analyzing past performance is overall return and volatility

Using these two metrics, we can determine if this stock gave its investors enough return for the risk that they took on by owning it. This is measured by the sharpe ratio, which has been used as a primary measure of risk/reward trade-off for almost 60 years.

This ratio can be interpreted as the amount of return an investor has received for the amount of risk that they took on by owning the stock over that timeframe.

Alterity Therapeutics (ATHE) sharpe ratio over the past 5 years is -0.5760 which is considered to be below average compared to the peer average of -0.2774